(Q42281083)

19 October 2017

Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis (English)

1 reference

19 October 2017

1 reference

visceral leishmaniasis

1 reference

1 reference

R Badaró

1

1 reference

19 October 2017

C Nascimento

2

1 reference

19 October 2017

J S Carvalho

3

1 reference

19 October 2017

F Badaró

4

1 reference

19 October 2017

D Russo

5

1 reference

19 October 2017

J L Ho

6

1 reference

19 October 2017

S G Reed

7

1 reference

19 October 2017

W D Johnson

8

1 reference

19 October 2017

T C Jones

9

1 reference

19 October 2017

1 January 1994

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

19 October 2017

1 reference

19 October 2017

13 Suppl 2

1 reference

19 October 2017

S23-8

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01973598

19 October 2017

0 references

cites work

A prospective study of visceral leishmaniasis in an endemic area of Brazil.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01973598

New perspectives on a subclinical form of visceral leishmaniasis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01973598

Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas

21 January 2018

1 reference

12 December 2020

Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine

1 reference

12 December 2020

Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma

1 reference

12 December 2020

Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans

1 reference

12 December 2020

Granulocyte-macrophage and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis

1 reference

12 December 2020

The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis

1 reference

12 December 2020

Interleukin-4 Inhibits Human Macrophage Activation by Tumor Necrosis Factor, Granulocyte-Monocyte Colony-Stimulating Factor, and Interleukin-3 for Antileishmanial Activity and Oxidative Burst Capacity

1 reference

12 December 2020

Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages

1 reference

12 December 2020

Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation

1 reference

12 December 2020

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

1 reference

12 December 2020

Recommendations for Treating Leishmaniasis with Sodium Stibogluconate (Pentostam) and Review of Pertinent Clinical Studies

1 reference

12 December 2020

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

1 reference

12 December 2020

Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis

1 reference

12 December 2020

Bacterial infections in patients with visceral leishmaniasis

1 reference

12 December 2020

Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory

1 reference

12 December 2020

Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis

1 reference

12 December 2020

Control of the leishmaniases. Report of a WHO Expert Committee

1 reference

12 December 2020

Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis

1 reference

12 December 2020

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).

1 reference

12 December 2020

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease

1 reference

12 December 2020

Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis

1 reference

12 December 2020

Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma

1 reference

12 December 2020

The effects of rhGM-CSF on macrophage function

1 reference

12 December 2020

Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01973598

1 reference

Dimensions Publication ID

19 October 2017

0 references

1 reference